Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced the execution of a license agreement for elvucitabine, the Company's nucleoside reverse transcriptase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE